Join us for the MediWound EscharEx Investor Day, featuring presentations by Key Opinion Leaders (KOLs) John C. Lantis, M.D. (Mount Sinai West Hospital and Icahn School of Medicine), Cyaandi R. Dove, D.P.M. (Advanced Wound & Ankle Center, Las Vegas), Robert J. Snyder, D.P.M., M.Sc. (Barry University) and Kevin Feng (Oliver Wyman).

These external experts will discuss the current wound debridement practice, the unmet need, the EscharEx recent clinical study results, as well as case studies that highlight the treatment experience.

In addition, KOLs will discuss the potential positioning of EscharEx for the treatment of patients and its competitive advantages while emphasizing its significant market opportunity.

EscharEx is a next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds.

MediWound’s Chief Executive Officer, Ofer Gonen, will moderate the session and provide a company update and discuss future strategic plans.

An expert panel Q&A session will follow the formal presentations.